White Paper

Considerations Regarding Noninferiority: A Case Study In Multiple Sclerosis

iStock-1140779660-drug-development-lab

Non-inferiority (NI) study designs are intended to determine whether a proposed (new) intervention is no worse than a reference intervention by a prespecified margin. Such designs frequently are encountered in development programs sponsored by the pharmaceutical industry, particularly in studies in which it would be clinically inappropriate to include an untreated control group and where the placebo effect (or standard of care effect) can be inferred reliably from existing historical data.

As with any study design, though, NI designs have specific attributes that must be accounted for to ensure that the design can adequately and justifiably address the research questions at hand. To illustrate the seven key elements that should be considered before selecting an NI study design, this paper presents a case study examining the potential use of an NI design in a study involving relapsing remitting multiple sclerosis (RRMS).

 

 

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: